AN2 Therapeutics
appears generally well tolerated in phase trial | AN2 Therapeutics
Company
Deck Type
Sector
Industry
Deck date
March 2025
Slide
14 of 36
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
February 2025
appears generally well tolerated in phase trial | AN2 Therapeutics
Related slides by other companies
Larimar Therapeutics
Investor Presentation
November 2023
appeared to be generally well tolerated in phase trial cohort | Larimar Therapeutics
9 Meters Biopharma
Investor Presentation
September 2022
vibrant phase trial design meters | 9 Meters Biopharma
MindMed
Investor Presentation
November 2024
phase trial schematic schematic | MindMed
Oculis
Results
August 2023
consistent results with in optimize trials | Oculis
Other recent decks by AN2 Therapeutics
See all presentations (4 decks)
Investor Presentation
February 2025
Investor Presentation
August 2022
IPO
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io